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Abstract: Many studies showed inconsistent cancer biomarkers due to bioinformatics artifacts. In this paper we use mul-
tiple data sets from microarrays, mass spectrometry, protein sequences, and other biological knowledge in order to improve 
the reliability of cancer biomarkers. We present a novel Bayesian network (BN) model which integrates and cross-annotates 
multiple data sets related to prostate cancer. The main contribution of this study is that we provide a method that is designed 
to ﬁ  nd cancer biomarkers whose presence is supported by multiple data sources and biological knowledge. Relevant bio-
logical knowledge is explicitly encoded into the model parameters, and the biomarker ﬁ  nding problem is formulated as a 
Bayesian inference problem. Besides diagnostic accuracy, we introduce reliability as another quality measurement of the 
biological relevance of biomarkers. Based on the proposed BN model, we develop an empirical scoring scheme and a 
simulation algorithm for inferring biomarkers. Fourteen genes/proteins including prostate speciﬁ  c antigen (PSA) are iden-
tiﬁ  ed as reliable serum biomarkers which are insensitive to the model assumptions. The computational results show that 
our method is able to ﬁ  nd biologically relevant biomarkers with highest reliability while maintaining competitive predictive 
power. In addition, by combining biological knowledge and data from multiple platforms, the number of putative biomark-
ers is greatly reduced to allow more-focused clinical studies. 
Introduction
Biomarkers, in the context of cancer diagnosis, usually refer to speciﬁ  c genes and their products which 
are indicators of disease states and can be detected in clinical settings. Microarrays and mass spectrom-
etry, a pair of complementary tools for studying genome activity and proteome activity respectively, 
have emerged to bring hopes for discovering biomarkers and building diagnosis models. The idea is to 
screen genome or proteome activity with microarray or mass spectrometry to ﬁ  nd a panel of biomarkers 
(usually ﬁ  ve to 20) and use them to build a diagnosis model that could outperform established single-
protein biomarkers, such as PSA (Prostate Speciﬁ  c Antigen) for prostate cancer and CA-125 (Cancer 
Antigen) for ovarian cancer (Diamandis, 2004).
The large-scale screening of genes and their products made the technologies extremely appealing 
not only for diagnosis but also for ﬁ  nding treatment for the diseases. Numerous studies have been 
performed on data sets using either microarray (Liu et al. 2005; Golub et al. 1999; Statnikov et al. 2005; 
Singh et al. 2002) or mass spectrometry (Lilien et al. 2003; Petricoin, 2002b; Petricoin et al. 2002a; 
Wagner et al. 2004; Liu and Li, 2005) technology. Many of these studies showed performance superior 
to current clinical biomarkers such as PSA for prostate cancer diagnosis. Although the biotechnology 
behind microarrays is fundamentally different from that of mass spectrometry, the strategies for biomarker 
ﬁ  nding and predictive model building are similar. They can be considered as a three-step data mining 
procedure. 1. Data generation and preprocessing: both healthy and ill patients’ data are collected; the 
data are usually preprocessed by normalization, outlier detection, baseline correction (in mass spec-
trometry), etc. 2. Computational biomarker extraction: standard tools such as ANOVA (ANalysis Of 
VAriance), t-test, PCA (Principal Component Analysis) and GA (Genetic Algorithm) can be used to 
select a small panel of genes in microarray or mass-to-charge ratios (m/z) in mass spectrometry. 
3. Classiﬁ  cation model building: standard classiﬁ  cation tools, such as SVM (Support Vector Machine), 
DT (Decision Trees), DL (Decision List), kNN (k-Nearest Neighbors), etc., are routinely used to build Cancer Informatics 2007:3 184
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predictive models based on selected biomarkers. 
Note that in some studies, steps 1and 2 or steps 2 
and 3 are combined. 
Our study focuses on the biomarker extraction 
step because the quality of the extracted biomarkers 
holds the potential for reliable diagnosis and treat-
ment of the diseases. The extraction of consistent 
and biologically relevant biomarkers can also 
signiﬁ  cantly improve our understanding of the 
disease and its mechanisms. However, many issues 
exist in this area due to either technology limita-
tions or computational artifacts which have been 
extensively discussed in the literature (Diamandis, 
2004; Conrads et al. 2003; Sorace and Zhan, 2003). 
For example, several studies showed inconsistent 
sets of biomarkers extracted for prostate cancer 
(Diamandis, 2004; Sorace and Zhan, 2003; 
Baggerly et al. 2004). Lacking conﬁ  rmation of 
disease-speciﬁ  c biomarkers posed a huge problem 
in the clinical application of both mass spectrom-
etry and microarray data. 
From the data mining point of view, biomarkers 
extraction from both mass spectrometry and micro-
array suffers from “curse of dimensionality” 
(Bellman, 1961); that is, the number of candidate 
biomarkers (usually thousands) is much greater 
than the number of samples or patients (usually 
dozens) in the study. A direct implication is that 
the search space for candidate biomarkers is too 
large for the small number of constraints so that 
the resultant biomarker solution will not be stable. 
An analogy is that, in a linear equation system 
when the number of unknown parameters is greater 
than the number of equations, there could be 
multiple (or an inﬁ  nite number of) solutions. This 
inconsistency indicates that the biomarkers are 
largely determined by the search algorithm used 
in the study. It was also reported that the cryptic 
biomarkers or noise peaks could result in “good” 
classification of healthy and cancer samples 
(Sorace and Zhan, 2003).
The quality of selected biomarkers is usually 
determined by their predictive power—that is, 
accuracy in predicting new samples. Due to the 
foregoing reasons, we introduce another quality 
measurement of biomarkers, reliability, which is 
deﬁ  ned as the probability of a gene being a true 
biomarker given the experimental data. Biomarker 
extraction strategies include ﬁ  lters, which select 
biomarkers independent of the choice of classiﬁ  ers, 
and wrappers, which search biomarkers by opti-
mizing given classiﬁ  ers. We take the ﬁ  lter approach 
because wrappers are classiﬁ  er-dependent and tend 
to capitalize on chance especially for large-scale 
microarray and mass spectrometry data (data 
having dimension curse). Therefore, our goal is 
not to invent another search algorithm which picks 
up one set of biomarkers from possibly many 
biomarker sets. Instead, our approach is designed 
to narrow down the number of candidate 
biomarkers so that their presence is supported by 
multiple experimental platforms. While previous 
studies focus on extracting biomarkers from either 
microarray or mass spectrometry data sets inde-
pendently, our approach is to associate microarray 
and mass spectrometry biomarkers to cross-vali-
date their existence by the evidence from each. We 
use multiple data sets including mass spectrometry 
and microarray profiles to introduce more 
constraints to the biomarker extraction system. In 
addition, we apply available biological knowledge 
in the biomarker extraction process to further limit 
the search space and obtain a very small list of 
biomarkers.
We introduce the concept of reliability, which 
is the posterior probability of a protein being a 
biomarker after seeing the experimental mass 
spectrometry and microarray data. This Bayesian 
concept is mathematically deﬁ  ned in section 3 
and calculated using our proposed Bayesian 
network (BN) model. Intuitively, if a gene 
biomarker shows evidence in microarray data and 
its associated peaks also appear in the mass spec-
trometry markers, this biomarker shows high 
reliability and we have greater belief that the gene 
and its products could be a reliable biomarker. In 
addition to the computational prediction accuracy, 
reliability is another performance measurement 
of putative biomarkers and it is very important in 
multi- or cross-platform biomarker analysis.
We ﬁ  nd that the BN model and its algorithms 
are especially effective in integrating multiple 
heterogeneous data and performing biomarker 
extraction and analysis. Relevant biological knowl-
edge can be built into the model by the use of 
proper prior parameters and appropriately designed 
network structure. The biomarker extraction 
problem can be nicely formulated as a probability 
inference problem and efﬁ  ciently solved using an 
existing inference algorithm. To connect speciﬁ  c 
proteins and mass spectrometry data, an algorithm 
is developed by simulating post-translational modi-
ﬁ  cations (PTMs) of proteins. The computational 
results show that our method can ﬁ  nd biomarkers Cancer Informatics 2007:3 185
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with the highest reliability while maintaining 
competitive predictive power. In addition, by 
combining biological knowledge and data from 
multiple platforms, the number of candidate 
biomarkers is greatly reduced, allowing more-
focused on clinical studies. 
Study design and data processing
The ﬂ  owchart of this study is displayed in Figure 1. 
The raw mass spectrometry and microarray data 
are pre-processed through a few steps and become 
pre-biomarkers. Basically the pre-biomarkers are 
genes or peaks that are expressed differentially in 
cancer and healthy samples. The pre-biomarkers 
are used for inferring biomarkers in our BN model. 
The details of each component in the ﬂ  owchart are 
explained in the following sections.
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Figure 1. Study design of biomarkers extraction and their application in disease prognosis. Peak detection, alignment, and peak selection 
are performed on the mass spectrometry data. Gene selection is performed on microarray data. Then the pre-biomarkers are ﬁ  ltered using 
a Bayesian network model to obtain ﬁ  nal biomarkers.
Data description
We applied our method to the data sets containing 
both microarray and mass spectrometry data from 
prostate cancer patients and healthy controls. The 
microarray data was obtained from Singh et al. 
(2002) and the mass spectrometry data from Petricoin 
et al. (2002b). The microarray data set contains high-
quality expression proﬁ  les obtained from 52 prostate 
tumor samples and 50 prostate non-tumor samples, 
using oligonucleotide microarrays containing probes 
for 12,600 human genes and ESTs (Expressed 
Sequence Tags). The mass spectrometry data set 
contains 69 cancer samples (26 samples with PSA 
level 4–10 ng/mL and 46 samples with PSA level 
greater than 10 ng/mL), and 63 normal samples with 
no evidence of cancer (PSA level less than 1 ng/mL). 
It was collected using an H4 protein chip and a 
Ciphergen PBS1 SELDI-TOF (Surface-Enhanced Cancer Informatics 2007:3 186
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Laser Desorption and Ionization Time of Flight) 
mass spectrometer. The data description can be found 
in (Petricoin et al. 2002b) and the data can be down-
loaded at http://home.ccr.cancer.gov/ncifdapro-
teomics/ppatterns.asp. It is important to note that the 
mass spectrometry samples are from serum while 
the microarray samples are from prostate tissues. 
The spectra were exported with the baseline 
subtracted. The m/z values range from 0 to 20,000. 
The sample proteins were not processed by external 
proteases such as trypsin. However, serum proteins 
are frequently found to be cleaved by chymotrypsin, 
trypsin and elastase (Richter et al. 1999) so that the 
mass spectrometry data reflect cleaved protein 
segments rather than intact proteins.
Before we make use of the BN model to ﬁ  nd 
reliable biomarkers, the microarray and mass spec-
trometry data were ﬁ  rst independently cleaned, 
adjusted, and transformed into a form that is able 
to be processed by a BN. We performed peak detec-
tion and peak alignment on the raw mass spectrom-
etry data, and extracted pre-biomarkers from both 
mass spectrometry and microarray data. Pre-
biomarkers, as the ﬁ  nal preprocessed data sets, 
refer to the differentially expressed genes or peaks 
in cancer and control samples. 
Peak detection from mass spectra
The raw spectrum for each sample is composed of 
15,154 (x, y) pairs, where x axis records m/z values 
with corresponding intensity on y axis. Therefore, 
we have 15,154 features for only 132 samples. Obvi-
ously the number of features is too large to build a 
reliable diagnosis model. The peak detection is the 
ﬁ  rst step in reducing the number of features. Peaks 
are basically the features which have local maximum 
intensities. Current peak detections are usually made 
by the software bundled with a spectrometer and 
hence the algorithms are hidden from users. The 
algorithm we use here is very simple and straight-
forward: we register all the m/z values if the corre-
sponding peaks (local maximum intensity) exceed 
user-speciﬁ  ed thresholds. We use both absolute 
threshold (intensity from baseline) and relative 
threshold (intensity from both the left and the right 
hill feet of the peak). Both thresholds are empirically 
set by a human annotator at 0.3.
Peak alignment
We applied the time-warping algorithm (Wang and 
Isenhour, 1987) to aligning the peaks extracted 
from each sample. The time-warping algorithm 
employs dynamic programming and is very similar 
to the global sequence alignment algorithm. After 
peak detection and alignment, the mass spectra still 
contain 6,467 features (aligned peaks) with m/z 
value above 1,000. The number of features is 
further reduced to 5,709 by requiring that a peak 
must be observed in at least two samples to avoid 
noise peaks.
Pre-biomarker (gene, mass peak) 
selection
Pre-biomarkers, as the ﬁ  nal preprocessed data sets, 
refer to the genes or peaks that are informative in 
the sense that they are differently expressed in 
cancer and control patients. Selecting pre-
biomarkers is a common practice which can 
significantly reduce the data dimension. The 
methods for extracting informative genes or mass 
peaks are essentially the same. In this study, we 
use the t-statistic with permutation test (Golub et al. 
1999). For each gene or mass spectrum, we 
compute the t-statistic using two group labels. Then 
we randomly permute the labels 10,000 times to 
see whether the t-statistic is signiﬁ  cantly correlated 
with class labels. The level of signiﬁ  cance α for 
an individual test is set at 0.0005. Note that multiple 
statistical tests could result in many false-positive 
biomarkers by chance. To overcome this problem, 
we use Bonferroni correction to adjust the level of 
signiﬁ  cance. This step yields 1,398 signiﬁ  cant 
mass peaks (908 over-expressed and 490 under-
expressed in cancer samples) and 240 gene (261 
over-expressed and 175 under-expressed in cancer 
samples) as pre-biomarkers. Note that other selec-
tion criteria such as False Discovery Rate (FDR) 
(Benjamini and Hochberg, 1995; Pawitan et al. 
2005), Fisher criterion, and F-statistics, can also 
be applied to biomarker feature selection.
A BN Model for Biomarker Extraction
A BN (Pearl, 1998; Heckerman et al. 1995) is a 
graph-based model for representing probabilistic 
relationships between random variables. The random 
variables, which may represent data source such as 
gene expression levels, are modeled as graph nodes; 
probabilistic relationships are captured by directed 
edges between the nodes, and the conditional prob-
ability distributions associated with the nodes. The 
BN model is convenient for approximating complex 
joint distributions among several entities. A direct Cancer Informatics 2007:3 187
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edge between two nodes indicates their direct depen-
dency. Formally, a BN for a set of random variables 
is a pair B = G, Ψ, where the ﬁ  rst component, 
G, is the network structure, and the second compo-
nent, Ψ, is the numerical parameters for conditional 
distributions P(X|parents(X)) associated with each 
node X. A BN can be viewed as a probabilistic expert 
system which encodes a set of knowledge and makes 
inference based on observations.
Biological rules
The preprocessed pre-biomarkers are the input 
(observations) to the BN model. The output would 
be the ﬁ  nal cancer biomarkers of interest. The 
design and implementation of the BN model are 
guided by the biological knowledge extracted from 
literatures and from experts in cancer and blood 
biology. The rules are as follows:
1) Over-expressed: With a few exceptions, the most 
promising cancer biomarkers are over-expressed 
in cancer patients (Diamandis, 2004).
2) Serum proteins, which are the most promising 
biomarkers, contain a mixture of secreted pro-
teins and species shed into blood circulation 
from diseased dying or dead cells present 
throughout the body (Conrads et al. 2003).
3) Signal peptides: Some proteins possess a signal 
peptide—a short peptide (15–60 amino acids 
long) that directs the post-translational transport 
of a protein. The existence of signal peptides is 
an important factor in determining whether a 
protein is secretory or not.
4) Ionized peptides: Ionized peptides generated in 
SELDI (Surface-Enhanced Laser Desorption 
and Ionization) mass spectrometry are pre-
dominantly singly charged (Siuzdak, 2003).
5) Amino acid modiﬁ  cation: Certain amino acids 
can be modiﬁ  ed by chemical groups. Common 
modifications include carboxylation, phos-
phorylation, oxidation, etc.
6) Peptide fragments: Peptide fragments, rather 
than intact proteins, are the predominant form 
(greater than 95%)  in human serum (Adkins 
et al. 2002; Richter et al. 1999).
7) Proteolytic cleavage: Most proteins undergo 
proteolytic cleavage following translation. In 
particular, serum proteins are frequently found 
to be cleaved by chymotrypsin, trypsin and 
elastase (Richter et al. 1999).
8) Signal peptide cleavage: signal peptides must 
be cleaved to reﬂ  ect the true mass spectra.
The ﬁ  rst three rules are general and used to 
guide our overall BN model design. We are most 
interested in the genes with elevated mRNA levels 
detected by microarrays and those whose protein 
products are secreted into the circulatory system 
and detected by mass spectrometry as over-
expressed peaks. To accommodate rule 1, we focus 
only on over-expressed genes and peaks in patients 
in this study. For rules 2 and 3, we explicitly model 
the inﬂ  uence of secretory proteins because they 
are a key factor in connecting the microarray and 
mass spectrometry data. We use the outputs from 
the SignalP 3.0 server (Bendtsen et al. 2004) to 
determine whether a protein is possibly secreted 
or not just based on its N-terminal sequence. The 
SignalP server uses an algorithm based on the 
Hidden Markov Model (HMM) (Nielsen and 
Krogh, 1998) which outputs the probability of a 
protein containing a signal peptide and the position 
of the cleavage site.
For rule 4, we simply assign a small probability 
to the peptides having double or higher charges. 
Rules 5–8 are mainly concerned about PTMs which 
signiﬁ  cantly affect the mass spectrometry patterns. 
Many proteins are synthesized as inactive precur-
sors that are activated under proper physiological 
conditions by limited proteolysis. A protein may 
undergo numerous PTMs so that it could be present 
in many forms at one time in the sample. Proteins 
and the mass spectrometry data are connected by 
theoretical mass spectra which are stochastically 
simulated using rules 4–8. The simulation is 
designed based on probabilistically modeling the 
biological knowledge about the modiﬁ  cation of 
nascent proteins and the SELDI system. There is 
also some quantitative knowledge about PTMs. 
Speciﬁ  cally, about 30% of all mammalian proteins 
are phosphorylated (Liebler, 2001), and more than 
90% of peptide fragments are proteolytically 
cleaved by trypsin, chymotrypsin or exoproteinase 
(Richter et al. 1999). These rules help us to assign 
proper prior probabilities for the PTM events. 
A BN model for biomarker ﬁ  nding
The data entities and knowledge are modeled as a 
BN shown in Figure 2. The variable “Protein” is 
to model the probability distribution of all proteins 
to be biomarkers. The prior distribution for Protein 
is uniform, indicating every protein has the same 
probability to be a biomarker. Since the choice of 
Protein determines its microarray pattern and its Cancer Informatics 2007:3 188
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probability to contain a signal peptide, we have 
edges from the node Protein to nodes MA 
(microarray) and SP (signal peptide) respectively. 
The Protein node together with the PTM nodes 
determines the pattern of the theoretical mass 
spectra (denoted as MS
T) of speciﬁ  c proteins. The 
variable MS
E represents the experimental mass 
spectra which contain a mixture of a large number 
of proteins and peptides from serum. MS
T is 
introduced to connect Protein with MS
E and to help 
annotate the mass markers at the protein level. 
Single-circled nodes are hidden variables in the 
sense that their values are not observed by the 
experiments, while double-circled nodes indicate 
observed variables which are used to model the 
outputs from MA, SP, and MS (mass spectra) 
respectively. Node MS
T is shaded to indicate it is 
a non-founder hidden variable. Nodes without 
parents are founder variables whose prior distribu-
tions need to be speciﬁ  ed. 
Beta distributions are used to model our prior 
belief of the occurrence of each PTM. (See 
supplementary information for Beta distribution and 
its simulation.) The prior distributions for the founder 
nodes are set up according to rules 4–8, and their 
effects on amino acids (AA) are displayed in Table 1. 
Each PTM event on the protein sequence can be 
treated as a Bernoulli trial with probability of success 
θ ~ Beta (α1, α2) where α1, α2 are parameters to 
specify the belief distribution. In order to use a BN 
for inference, we also need to specify the conditional 
probability distribution P(X|parents(X)) for every 
non-founder node X. We will discuss these condi-
tional probability distributions in the next section.
Phospho.
Protein
Charge Trypsin …
MSE
MST MA
SP
Signal
Position …
Figure 2. Proposed BN model for biomarker ﬁ  nding.
The variable MS
T is a hidden node. Its condi-
tional distribution, given a protein sequence and 
all the PTM probabilities, is determined by simu-
lation. MS
T for a single protein is represented in 
the following format: 
  MS
T={(mzj, fj)| j = 1, ..., r} (1)
where mzj is the m/z ratio, fj is the frequency of the 
jth peak, and r is the number of peaks generated 
by simulation of the protein. 
We use PRO to denote the set of all proteins in 
the universe of discourse. Other variables MA, SP 
and MS
E are observed and they are used to model 
the outputs from the preprocessed experimental 
data sets. MS
E, MA and SP are represented in the 
following format:
 
MS mz i n
MA t protein PRO
SP p p
E
i
protein
protein
==
=∈
=
{ | ,..., }
{| }
{|
1
r rotein PRO ∈ }
 (2)
where n is the number of pre-biomarkers of mass 
spectra after preprocessing; tprotein is the t-score for 
the protein in the microarray experiments; and pprotein 
is the probability of the protein containing a signal 
peptide generated by the SignalP 3.0 server. 
Using our BN model, the biomarker extraction 
problem can be regarded as a classic Bayesian 
posterior probability inference problem. The poste-
rior probability of interest is the probability of a 
protein given the observation of MS
E, MA, and SP. 
The objective is to ﬁ  nd a set of biomarkers with 
the highest posterior probabilities.Cancer Informatics 2007:3 189
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Simulation and Scoring
The goal of the simulation algorithm is to 
generate MS
T patterns by applying rules 4–8 as 
random events. For each amino acid in the protein 
sequence, we tested every PTM to see whether 
a PTM is possible at that position. If it is possible, 
we draw a sample θ from Beta (α1, α2) as the 
prior distribution for that PTM. Then we 
performed a Bernoulli trial with a probability of 
success θ. If the trial is successful, we perform 
the PTM on the protein sequence; otherwise we 
skip the PTM. We repeated the simulation 1,000 
times and recorded the peak distribution as MS
T 
for that protein.
Simulation Algorithm
Input: a protein sequence and the prior distribution 
of all PTMs where residue position is indexed by 
i, PTM is indexed by j.
OutPut: MS
T for the protein
for (each position i in the protein sequence)
 for (each PTM j) 
  i f  (position i meets the constraint of PTM j)
   1. Draw X ~ Beta (α1, α2);
   2. Draw Y ~ U(0,1);
   3. if Y < X, perform modiﬁ  cation; otherwise,
        no modiﬁ  cation; 
  endif 
  else try next PTM j + 1;
Table 1. Founder nodes (Protein and PTMs), their effects on the mass spectra pattern and their prior distributions.
Founder node  Affected AA  m/z difference  Prior probability
Carboxylation  C  +58.005479  Beta (2, 5)
Phosphory  T,S,Y  +79.966330  Beta (2, 2)
Water loss  S,T  –18.010565  Beta (2, 5)
Oxidation  M  +15.994915  Beta (2, 5)
Doubly charged  parent peptide   parent m/z + 1
2
  Beta (2, 10)
Trypsin  after K/R except 
  before P  --  Beta (8, 2)
Chymotrypsin after  FLWY, 
  except before P  --  Beta (8, 2)
Loss AA after   N-terminal, 1–4 
cleavage  AA lost  --  Beta (2, 10)
Signal  Determined by     Determined by
Position  SignalP 3.0  --  SignalP 3.0
Protein --  --  Uniform
 endfor
  go to next position i + 1;
endfor
When the end of the protein sequence is reached, 
record m/z of simulated peptides in MS
T;
Repeat the above procedure 1,000 times and 
output MS
T;
Figure 3 shows an example MS
T simulation of a 
protein with GI 9955963. Note that the y axis shows 
the frequency of each peak in 1,000 simulations (not 
the intensity of standard mass spectra outputs). A red 
peak (bold line) means the peak matched a peak in 
the MS
E pre-biomarker, while a blue one (thin line) 
means unmatched. By simulating and matching MS
T 
against MS
E, we built the connection between a protein 
and experimental mass spectra.
The BN allows us not only to conveniently 
represent the biological knowledge but also to 
analyze and formalize the problem of biomarker 
extraction. The posterior probability of a protein, 
which is of our interest, is computed as follows
 
P protein MS MA SP
P protein MS MA SP
PM S M AS Pp r
E
E
E
(| , , )
(, , , )
(, , |
=
=
α
α o otein P protein
P MA protein P SP protein
PM S p r o t e i
E
)( )
'( | )( | )
(|
=α
n n)
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where α and α' are constants independent of the 
choice of proteins. The ﬁ  rst and second equations 
directly follow Bayes’ theorem while the third 
equation follows the conditional independence 
deﬁ  ned by our BN model structure. The last factor 
can be simpliﬁ  ed as follows:
 
P MS protein
P MS MS protein
P MS MS protein
E
ET
MS
ET
MS
T
(| )
(,| )
(|, )
=
=
∑
T T
P MS protein
PM S M S
T
ET
∑
=
(| )
(|)
 (4)
where the ﬁ  rst and second equations follow the 
definition of marginal distribution; the third 
equation is validated by observing that MS
T is a 
deterministic variable given the protein sequence 
so that P(MS
T|protein) =1; and MS
E is independent 
of the protein given MS
T.
The above analysis indicates that the score of a 
protein can be decomposed into three parts: its 
likelihood containing a signal peptide, its micro-
array proﬁ  le, and its mass spectra pattern. Since 
the likelihood terms are difﬁ  cult to deﬁ  ne and 
estimate (except for SP), we further generalize this 
equation into a form that can be determined 
empirically,
 
S protein S MA protein S SP protein
SM S
E
() ( |) ( |)
(|
=
p protein).
 
(5)
This score S(protein) is called the reliability of 
biomarkers which is a generalization of the 
posterior probability in Equation (3). Now the 
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Figure 3. Example of MS
T simulation results. The range of m/z values between 1,400 and 3,000 is magniﬁ  ed to show the detail of MS
T pattern.
problem of biomarker ﬁ  nding can be formalized 
to ﬁ  nding the set of proteins which have the highest 
reliabilities:
 { protein|S(protein) > σ} (6)
where σ is a user-deﬁ  ned threshold to determine 
whether a reliability of a protein is high enough to 
make this protein a candidate biomarker.
The score for SP is deﬁ  ned as follows:
  S(SP | protein) = pprotein (7)
where pprotein is the output of the HMM model in 
the SignalP Server.
Since we are only interested in over-expressed 
genes, we use a sigmoid function to deﬁ  ne the score 
for MA outputs. See Figure S1 in supplementary 
information for an illustration of the function:
  S MA protein
tprotein
(| )
exp( )
. =
+− +
1
1 σ  (8)
To deﬁ  ne the likelihood term S(MS
E|Protein), we 
ﬁ  rst deﬁ  ne S'(MS
E|Protein), which is the raw score 
of observing the experimental spectra given a 
protein,
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where length is the number of amino acids contained 
in the protein; MS
E ∩
 MS
T denotes the set of peaks Cancer Informatics 2007:3 191
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shared (within a certain threshold) by the two 
spectra. WSPC (Weighted Shared Peaks Count) is 
the sum of all frequencies of the shared peaks greater 
than a certain threshold δ. WSPC is then divided by 
the length of the protein to eliminate the dependency 
between the raw score and length (see Figure S2 in 
the supplementary information).
The score S(MS
E|protein) is further normalized 
by dividing its raw score by the supremum of the 
scores for all proteins.
 S MS protein
SM S p r o t e i n
SM S p r o t e i
E
E
protein PRO
E (| )
'( | )
sup '( | '
=
∈ n n') 
(10)
We see that all the scoring deﬁ  nitions are properly 
normalized into the interval [0, 1]. Although some 
of them may not be interpreted to be probability, 
they could be used as empirical measurements for 
the extent of matching between a protein sequence 
and experimental results.
Biomarker Analysis and Results
We implemented the pre-processing modules, the 
BN model and its associated algorithms in Micro-
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Figure 4. Pre-biomarkers distributed in a space deﬁ  ned by the scores on each data set (MA, SP, MS). Every point on the mesh has a score 
S(protein) = 0.1; above the mesh, S(protein) > 0.1; under the mesh, S(protein) < 0.1.
soft™ Visual™ C++ 6.0. The post-processing and 
graphics was performed using Matlab™.
Distributions and p-value
We applied the BN inference algorithm and the 
scoring scheme to 240 protein pre-biomarkers 
obtained from microarrays (See supplementary 
Table S1 for the list of pre-biomarkers). Figure 4 
shows the scores plotted in the three-dimensional 
space with each dimension corresponding to one 
of the three components in Equation (5).
The 240 pre-biomarkers are roughly clustered 
at four of the corners in the space. There are only 
32 proteins above the mesh, indicating their reli-
abilities (scores) higher than 0.1. We will discuss 
why 0.1 was used as a score standard to select 
candidate biomarkers in the following paragraphs. 
This group of 32 proteins is notated as candidate 
biomarkers and most of them are clustered into a 
sphere as indicated in Figure 4. 
The BN method is also applied to all human 
protein sequences, including 12,484 sequences 
obtained from SWISS-PROT release 47.2 (Bairoch 
et al. 2005). The histograms in Figure 5 show the 
scoring distributions of all human proteins vs. 
candidate biomarkers. Figure 5a shows the scores Cancer Informatics 2007:3 192
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for mass spectra S(MS|protein). We see that the 
scores for the population (all human sequences) 
are distributed in a shape similar to exponential 
distribution (cases = 12,484, mean = 2.59, 
SD = 2.22). The scores for 32 candidate biomarkers 
have a higher mean but the two distributions are 
not sufﬁ  ciently separated (cases = 32, mean = 3.35, 
SD = 2.00).  Figure 5b shows the S(protein) distri-
butions of the candidate biomarkers and all human 
proteins. The candidate biomarker distribution is 
clearly separated from the population distribution 
and the number of candidate biomarkers is consid-
erably reduced as a result of introducing multiple 
data sets in our BN model. 
The distributions in Figure 5b could be used to 
construct a statistical test for the reliability. The 
null hypothesis (H0) states that a protein with a 
reliability score is randomly picked from the popu-
lation, while the alternative hypothesis (H1) states 
that the protein is NOT randomly selected from 
the population. If we use the reliability as the test 
statistic, we observed from Figure 5b that a 
reliability score greater than 0.1 corresponds to a 
p-value less than 0.01. This is the reason we use 
0.1 as a score standard to select candidate 
biomarkers. Caution should be taken when inter-
preting p-values. The statistical test determines 
Figure 5. Distributions of candidate biomarkers and all human proteins. a. Distribution of S(MS|protein); b. Distribution of S(protein).
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whether a protein with a speciﬁ  c reliability is likely 
due to chance (H0) or signiﬁ  cantly unlikely due to 
chance (H1). This indirect test is intended to simu-
late a direct test that determines whether the protein 
is a biomarker or not, but the two tests are not 
equivalent and the latter one can only be justiﬁ  ed 
by experimental study. Figure 5 also shows that 
the separating powers of each data source are not 
equal. Especially, the mass spectrometry data are 
not as discriminating as microarray data and signal 
peptide data. This can also been seen in Figure 4, 
where microarray and signal peptide data clearly 
separate all the points into four groups.
Sensitivity analysis
Although we specified the prior distributions 
according to biological rules, the BN model should 
be robust regardless of the choice of subjective 
parameters. Robustness is a characteristic of the 
model and its assumptions, while reliability is a 
characteristic of a protein given the model.
The robustness was studied by sensitivity anal-
ysis of how the prior parameters’ changes inﬂ  uence 
the inference of biomarkers. We assigned six sets 
of values (S1, S2, …, S6) to the parameters (amino 
acid PTMs, cleavage PTMs, the threshold δ, and the Cancer Informatics 2007:3 193
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number of simulation repeats). For each setting of 
parameters, we performed BN inference and selected 
20 candidate biomarkers with the highest scores. 
The values of the six sets of parameters are displayed 
in Table 2 and the results of corresponding 
biomarkers are summarized in Figure 6. Not surpris-
ingly, we found that the inference is relatively sensi-
tive to the parameters of cleavage PTMs, as we 
observed that the biomarkers obtained with the 
parameter sets S1 and S2 diverge from those 
obtained with the other four parameter settings. 
However, 14 proteins are consistently found in at 
least ﬁ  ve of the six sets, and six of them appear in 
all six parameters sets. These 14 biomarkers and 
their scores are summarized in Table 3.
All of the 14 proteins are over-expressed in 
cancer tissues and very likely to contain a signal 
peptide. All 14 proteins have signiﬁ  cant reliability 
scores (p-values < 0.01) and relatively high mass 
spectrometry scores, indicating that their MS
T 
(theoretical mass spectra) match MS
E (experi-
mental mass spectra) to a relatively large extent. 
An immediate ﬁ  nding is that PSA (APS) (in Table 3), 
probably the only biomarker that is employed in 
current clinical practice, is identified by our 
method. The identiﬁ  cation of PSA as a reliable and 
robust biomarker strongly suggests that our method 
is effective in ﬁ  nding biologically meaningful 
biomarkers. We performed a manual OMIM 
(Online Mendelian Inheritance in Man) (OMIM, 
2000) search for the functions of the 14 proteins. 
CANX and CRTC have a high afﬁ  nity to binding 
calcium ions, indicating their roles in the regulation 
of signal transduction. Immunoglobulin IGSF4B 
and LU are cell adhesion molecules, and they play 
roles in cancer regulation (Fukuhara et al. 2001; 
Rahuel et al. 1996). CDH12 are calcium-dependent 
cell-cell adhesion molecules that may be involved 
in the metastasis and invasion of cancer. By 
matching MS
T to MS
E for the 14 proteins, we iden-
Table 2. Six sets of parameter settings where S4 is the 
default setting.
 S1  S2 
S3 S4  (Default)  S5 
S6
AA PTM Beta(α1, α2) (2,2)  (2,2) 
(2,2) (2,2)  (1,1) 
(2,2)
Cleavage PTM Beta(α1, α2) (3,7)  (3,7) 
(8,2) (8,2)  (8,2) 
(8,2)
Threshold δ 20  50 
20 50  20 
20
Repeats 1000  1000 
1000 1000  1000 
500
tiﬁ  ed 20 unique peaks in the sense that each peak 
is associated with only one protein among the 14 
proteins. The m/z values and their associated 
peptides are displayed in supplementary Table S2. 
A complete discussion of the 14 proteins is beyond 
the scope of this paper, but, they deserve further 
studies including biological experiments. 
To test the classiﬁ  cation accuracy, we performed 
a classiﬁ  cation study on the set of biomarkers using 
SVM
lignt (Joachims, 1999) as the classiﬁ  er. The 
SVM
lignt was set at default with a linear kernel. The 
leave-one-out estimates of the 14 protein 
biomarkers, 20 associated unique peaks, and PSA 
microarray data are displayed in Table 4. The clas-
siﬁ  cation accuracy shows that using panels of 
either microarray or their associated mass spec-
trometry biomarkers certainly outperforms using 
PSA as the sole biomarker. Our classification 
performance is comparable to the original reports 
(Petricoin et al. 2002b; Singh et al. 2002). They 
use searching-based strategies (wrappers) and 
search for biomarkers that maximize certain clas-
siﬁ  ers. However, our approach, instead of using a 
wrapper, uses a sophisticated ﬁ  lter which is clas-
siﬁ  er independent, and therefore less likely to be 
cryptic. In addition, our solution is supported by 
multiple biological evidences. Recall that, due to 
the “dimension curse”, there are many sets of 
biomarkers which have essentially equivalent 
discriminative power, and the determination of a 
solution depends on the searching path of a speciﬁ  c 
algorithm. But our approach could ﬁ  nd the most 
reliable biomarkers at the meanwhile maintaining 
their diagnostic accuracies. 
Discussion
Our method built relationships between the 
biomarkers at both mRNA and protein levels, 
helping cross-validate the biomarkers obtained from Cancer Informatics 2007:3 194
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different data sources. The candidate proteins 
revealed from our method, including PSA, are 
related to prostate cancer, which indicates our 
method is effective in ﬁ  nding biologically relevant 
biomarkers. By using data from multiple platforms, 
our method narrowed down thousands of putative 
gene biomarkers to the extent that the biomarkers 
can be studied individually. Among many thousands 
of genes, the list of gene biomarkers not only shows 
competitive predictive power but more importantly, 
shows the highest reliability meaning that their 
existence is supported by multiple sources of data. 
Unlike the samples for peptide mass ﬁ  nger-
printing which are enzymatically digested proteins 
Figure 6. Sensitivity analysis results. Each column represents a biomarker and each row represents a parameter set. A black or gray square 
corresponds to presence or absence of a biomarker under a certain set of parameter. 
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Table 3. Biomarkers and their scores under default parameter setting.
GI Gene  Name  Function  MS  MA  SP  Score
16418409 PORIMIN  cell  death  1.00  0.92  0.99  0.93
12643880 STK39  S/T  kinase  0.40  0.88  0.95  0.34
71834853 PSA  Androgens  regulated  0.34  0.95  0.99  0.32
16445393 CDH12  cell-cell  adhesion 0.31  0.99  0.99  0.31
7656967 CELSR1  protein-protein  interactions  0.33  0.89  1.00  0.30
11056046 IGSF4B(TSLC1)  Immuno-globulin  0.30 0.95 1.00  0.29
1708887 LU  Immuno-globulin  0.30  0.95  0.99  0.28
9297107  NRP1  cell growth factor  0.28  0.88  0.99  0.24
62512184 SEL1L  gene  regulation  0.25  0.95  1.00  0.24
4557575  FAAH  fatty acid amides  0.21  0.96  0.97  0.20
12751475 SLC39A6  zinc  transporter  0.21  0.94  0.99  0.19
10716563  CANX  calcium ion binding  0.18  0.97  0.99  0.18
14916999 GRP78  Protein  folding  0.20  0.89  1.00  0.18
117501  CRTC  calcium ion binding  0.17  0.93  1.00  0.16
after being puriﬁ  ed, our mass spectrometry samples 
are one-level-more complex because they consist 
of multiple unknown proteins which are then post-
translationally modiﬁ  ed in vivo. It is practically 
impossible to identify specific proteins from 
spectra made up of complexly mixed peptides as 
in serum. However, external controls (cancer vs. 
health samples), microarrays, and biological rules 
can facilitate the analysis and annotation of mass 
biomarkers. The greatest difﬁ  culty in using mass 
spectrometry data in our model is to associate 
individual proteins with the experimental mass 
spectrometry proﬁ  le. We know that individual mass 
spectrometry peaks from mixture samples such as Cancer Informatics 2007:3 195
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serum proteins cannot be accurately annotated to 
the sequence level without using tandem mass 
spectrometry. Our solution is to associate each 
individual protein NOT with individual peaks, but 
with the entire MS pattern so that the association 
of mass spectrometry data with each protein is not 
easily affected by individual peaks. This is done 
by simulating MS
T, which reﬂ  ects the existence of 
proteases and other PTM factors in serum, and 
comparing MS
T with MS
E. This strategy of linking 
proteins to mass spectra is supported by the fact 
that the protein biomarker PSA yields a large score 
(0.34) for its MS
T compared with MS
E. Admittedly, 
the existence and the use of biomarkers are not 
valid until they are clinically validated. However, 
with the resolution and sensitivity improvement of 
mass spectrometry technology, and with more 
cross-platforms, cross-labs becoming available, 
our computational model could shed more light 
into clinical studies.
Currently, there are no reliable computational 
methods to discriminate secreted proteins from 
membrane proteins. Some membrane proteins such 
as CANX (containing signal peptides) are inevi-
tably selected by our method, although our goal is 
to ﬁ  nd serum biomarkers. This example shows the 
importance of incorporating further biological 
knowledge into bioinformatics tools.
Distinguished with the methods focusing on 
applying search algorithms to a single data set, our 
method emphasizes the use of multiple data sets 
and biological knowledge to reduce the effect of 
bioinformatics artifacts and to enhance the reli-
ability and relevance of biomarker searching. The 
merit of the BN model lies in its power to explic-
itly represent and compute biological knowledge 
and multiple entities. 
Coombes et al. (2004) present a simulation-
based approach to understanding the physical 
factors of mass spectrometry instruments and their 
Table 4. SVM prediction performance using different biomarkers.
Leave-one-out Microarray  Microarray  Mass 
Estimates  14 markers  PSA only  Spectrometry 
20      
markers
Error 14.71  25.49  16.67
Recall 80.77  75.00  85.51
Precision 89.36  75.00 83.10
effects on the mass spectra. Note that our proposed 
simulation algorithm mainly focuses on how the 
biological factors (such as trypsin and other PTMs) 
in human blood affect the mass spectrometry 
patterns of speciﬁ  c proteins.
One limitation of our current study is that we 
used only one data set from each type of experi-
ments. It is possible that one error in the assay could 
change the conclusion on one biomarker. The power 
of our BN model lies in its ability to make inference 
on multiple observations—the more data it sees, 
the more accurate the results will be. To fully utilize 
the convenience of Bayesian models in biomarker 
analysis, we will include replicate data sets from 
multiple labs in future study. 
The biomarker ﬁ  nding and its clinical use is a 
very complex issue, and a completed discussion is 
beyond the scope of this article. Refer to Lyons-
Weiler (2005) for a review of the research in 
biomarker informatics. According to Pepe et al. 
(2001), our study is at the data exploratory phase 
of biomarker development and validation. Clinical 
assays and follow-up analysis are needed to 
conﬁ  rm our ﬁ  nding of prostate cancer markers.
In this study, we focused on integrating micro-
array and mass spectrometry data and made infer-
ence of biomarkers using a BN model. However, 
our approach is not limited to such usages. With 
the fact that biomarkers are now generated from 
different types of instruments, multiple labs, 
various sets of samples and controls, the data 
analysis of biomarkers will be becoming 
increasingly complex and the integration and meta-
analysis of multiple results will be attracting more 
attention in the near future. Our proposal of 
Bayesian strategy and the concept of reliability are 
important in evaluating biomarkers generated from 
heterogeneous platforms. 
In the proposed model, unknown patient 
samples are scored according to a scoring system Cancer Informatics 2007:3 196
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that is derived from gene-expression patterns of 
all training samples. Biomarkers based on a subset 
of samples or individual samples could allow the 
detection of subtle difference between subsets of 
samples and increase the overall prediction 
accuracy (Lyons-Weiler et al. 2004). The cross-
validation results, shown in Table 4, may be 
optimistic, because testing data and training data 
come from the same experiments so that the 
variances caused by instrumental and experimental 
factors are not included in the analysis. The use of 
independent test data sets will be another important 
step to further validate the prediction performance 
of cancer biomarkers (Lyons-Weiler, 2005).
We must also point out that the current biological 
knowledge base in the BN model is a limited version; 
we included a few general biological rules and three 
numerical data sets. We are currently working on 
expanding and improving the current BN model to 
incorporate gene-specific information such as 
PubMed, OMIM, and GO. It has been shown that 
BN models are ﬂ  exible and expandable to deal with 
complicated biological data types and data structures 
(Deng et al. 2005). Our long-term goal is to build a 
more intelligent knowledge engineering system 
which can “understand” complicated knowledge and 
extract biomarkers for more diseases.
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Beta Distribution and its Simulation
Beta distribution is denoted by Beta (α1, α2) where α1, α2 are parameters to specify the belief distri-
bution. Beta (α1, α2) has the mean 
α
αα
1
12 +  and the variance 
αα
αα αα
12
12 12 1 2
⋅
++ + () ( ) . For example, Beta (2, 3) 
express that the probability (belief) of the occurrence of the PTM is centered at 
2
32 0 4 + = . , and the stan-
dard deviation of this belief is 
23
23 231 2 0 2
⋅
++ + = () ( ) . ; Beta (20, 30) also has mean 
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Figure S1. Sigmoid function to deﬁ  ne the S(MA|protein) from t-value.
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Figure S2. The effect of protein length on the scoring of MS. Coefﬁ  cient of determination R2 drops from 0.72 to less than 0.01 by normal-
izing the score by the length. Clearly the linear dependency is largely eliminated by the normalization.Cancer Informatics 2007:3 199
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much smaller standard deviation 
20 30
20 30 20 30 1 2 0 069
⋅
++ + =
() ( ) . . Therefore, Beta distribution cannot only 
describe our belief of the occurrence of an event but the degree of uncertainty of our belief as well. The 
simulation of Beta distribution is performed via simulating Gamma distribution (See C++ code 
below).
double Beta (double alpha1, double alpha2)  double Gamma (double alpha) 
{  //gamma(alpha, 1), alpha >1
    double y1 = Gamma(alpha1);  {
    double y2 = Gamma(alpha2);      double a = 1/sqrt(2*alpha-1);
    return y1/(y1 + y2);      double b = alpha-log(4.0);
}      double q = alpha+1/a;
      double theta = 4.5;
      double d = 1 + log(theta);
  B:  double U1 = Uniform();
      double U2 = Uniform();
    double  V  =  a*log(U1/(1-U1));
    double  Y  =  alpha*exp(V);
      double Z = U1*U1*U2;
    double  W  =  b+q*V-Y;
      if(W + d-theta*Z> = 0)
   return  Y;
      else if(W> = log(Z))
   return  Y;
    else
   goto  B;
 }Cancer Informatics 2007:3 200
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Table S1. 240 pre-biomarkers obtained from MA, their t-score, and their HMM output.
 GI  t_protein  p_protein
  13904866 4.49 0.016
 113950  -6.97  0.001
  15431295 5.63  0
  15055539 7.32  0
 133041  6.52  0
 4506607  4.75  0
 1096944  4.75  0.001
 136479  4.35  0
 1082889  4.35  1
 4557647  4.33  0
  16753225 5.45 0.006
 4506699  4.46  0
 1096940  4.46  0
  13904870 4.87  0
  15220431 4.75  0
  11415026 6.34  0
  14591909 4.55  0
 266921  5.69  0
 1350706  5.77  0
 4506713  4.20  0
 133825  4.92  0
  15718687 4.67  0
  16579885 4.51 0.001
 2493600  -4.10  0.002
 116533  -5.06  1
 1095781  -5.06  0.986
 1708274  5.47  0
 7512733  5.47  0.01
 9910418  -4.45  0
 128117  4.71  0.998
 4557575  5.18  0.97
  12229574 -6.61  0.998
  25402878 -6.61  0
 7108362  5.72  0
 4759146  -4.65  0.996
 4557543  -4.05  0.998
 5803003  -4.06  0.002
  17366160 4.73 0.064
  17433099 -4.21  0
 7657603  5.61  0
 9955963  9.00  0.024
 7656967  4.10  1
  17374817 -4.23  0.045
 121148  4.72  0.726
 4885645  -5.26  0
 113954  4.11  0
 2497437  4.15  0.351
  12585545 4.47 0.001
  11352059 4.47  0
  12643308 5.28  0
 1345650  -4.99  1
 4826768  4.69  0
 4506701  -4.13  0
  17978471 4.23  0
  10190714 -4.68  0.003
  14602449 -4.45  1
 7512879  -4.45  0.045
  11321634 4.48  0
 5921743  -4.19  0.005
 GI  t_protein  p_protein
 6005824  -4.58  0.024
  11321603 -5.52  0
 4507547  4.79  0.001
 7662254  -4.58  0.001
 7512876  -4.58  0.986
  18490978 -5.60  0.367
  11356305 -5.60  0.115
  11360104 -5.60 0.001
 9297107  4.06  0.999
  50403775 -4.37  0.129
 3914303  -6.61  0.043
 2495731  -4.83  0
  18699734 4.19  0
 115945  -4.36  1
  13626119 -4.82  1
 123057  10.40  0.278
 399193  -4.01  0
 7657176  4.97  1
 4758626  -4.03  0.004
  12230067 -4.96  0.005
 133486  -5.75  0.001
 132387  -6.07  0
  13129026 4.04  0
 4503537  4.64  0
  68068024 5.93  0
  13129064 -5.13  0.006
 1585496  -5.13  1
 8134636  -5.25  0
 121735  -4.96  0.015
 4502109  -4.72  0
 4885559  -4.43  0.029
 11181775  -4.10  0
 5453722  4.20  0.373
  14165437 4.12  0
  11993943 -4.19  0
  13878821 4.29  0.75
 2135080  4.29  0
 1082633  4.29  0
 728834  -4.88  0.962
  10720334 5.12  0
 127442  5.75  0.235
 1708887  4.97  0.999
  10716563 5.79 0.999
 1351211  4.32  0
 113463  6.45  0.049
  14249524 4.79 0.999
  16418409 4.52 0.998
  10445223 4.63  0
 6679189  5.17  1
 133948  5.27  0.014
 117098  5.16  0.449
 125174  4.53  0.996
 5902014  4.97  0.005
 4504631  -4.18  0.002
 1173039  4.32  0
 1172922  4.27  0
 4505581  -4.33  0
 728833  -4.67  0.962
 4506699  4.46  0Cancer Informatics 2007:3 201
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 GI  t_protein  p_protein
 118504  -4.56  0.845
56405387 -5.21  0
 135304  4.70  0
 133701  -4.72  0.004
 4505623  -4.87  0.008
  11291391 -4.87  0
  11360002 -4.87 0.003
 127983  5.35  0
 7661670  5.50  0.001
 4502875  6.55  0.805
  13432136 4.97 0.353
 114322  6.07  0.001
  13878805 4.04 0.997
  10863909 4.03 0.999
  25398579 4.03  0
 5902020  -5.38  0
 4506427  -5.37  0.999
  12643622 7.07 0.627
 7512940  7.07  0.004
 728831  7.81  0.902
 4758792  4.18  0.215
  10835025 5.25 0.072
 4502877  4.21  0.978
 6912682  -4.88  0.999
  71834857 4.98 0.998
  13638228 4.93 0.004
 9994169  4.66  0.001
  18104976 4.07 0.703
 8393299  -4.23  1
 5453603  4.91  0.092
  14916573 4.81  0
 5031597  4.39  0.001
 4758950  4.60  0.863
  11056046 4.97  1
  13637934 -4.94  0
  25387602 -4.94  0
 1703205  4.04  0
 417246  5.19  0.002
 119172  6.46  0
 4507877  -5.34  0
  14916999 4.16  1
 1706396  4.46  0.884
 5803145  4.35  0
 1345695  -4.11  0
 231741  -5.46  0
 4758032  4.52  0
 4507357  -4.04  0
 6166568  4.21  0
  13994151 -4.42  0
  14548187 -5.17  0
 4885509  -4.34  0.997
 129483  4.32  1
 7657552  5.37  0.007
 1583602  5.37  1
 1589585  5.37  0.157
61252057 -5.02  0.99
16306550 -5.58  0
 5174485  -4.47  0.999
 4557617  -4.62  1
 114392  -4.35  0
16445393 10.05  0.999
 GI  t_protein  p_protein
 133116  4.19  0.581
 231475  -4.62  0
 6005924  -7.54  0
 115601  -5.92  0
 2495724  -4.68  0
 4505835  -5.17  0.541
  17380550 -4.16  0.006
 4757902  -5.67  0
  14149680 -4.04  0
 3024727  5.20  0.999
  50403771 4.54 0.051
 399866  4.88  0
  13124879 -4.47  0
 6226951  4.14  0
 5453541  5.68  0.999
 4826878  -4.21  0
 5729836  4.63  0
 1705731  -5.07  0.031
 7513030  -5.07  0.001
 8923881  4.34  0
 3915626  -7.40  1
 9257222  -4.77  0
 1705650  4.92  0
  12643880 4.09 0.958
  10047134 -5.06  0
  68846235 5.49  0
 121110  -4.54  0.995
 8923444  4.08  0
 126047  5.81  0
 5453736  -6.37  0
  62512184 4.95  1
 2135919  4.95  0
 117501  4.60  1
 5032159  -4.59  0.042
  55977848 4.51 0.557
  11348280 4.51 0.895
  13878450 -5.14  0
 4505037  -6.97  0.868
 6912268  -6.26  0.02
 131762  4.74  0
 127983  5.35  0
 226527  5.35  0
 4557355  -4.41  0
 4758936  4.70  0.996
  17402909 -4.46  0
  12751475 4.82 0.992
 1730015  5.55  0.427
  11352548 5.55  0
 4557617  -4.62  1
 226527  -4.62  0
 223828  -4.62  0.722
  17380263 4.12 0.014
 2842764  4.02  0.989
 113950  -6.97  0.001
  10835023 -4.30  0.007
 1352464  -4.16  0.001
 4758594  -4.31  0.992
 4557413  -4.46  0
 125969  5.58  0
 118295  4.50  0
 2829468  -4.69  0Cancer Informatics 2007:3 202
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Table S2. Speciﬁ  cation of 14 biomarkers identiﬁ  ed by our BN mothods.
GI  Description  Unique mass marker with peptide sequence   m/z (Da)
16418409  pro-oncosis receptor inducing  TTSVSQNTSQJSTSTM(4)TVTHNSSVTTAASSVTI  4347
  membrane injury gene   TTTMHSEAKK 
 ( PORIMIN)
12643880 STK39_HUMAN  VKEENPEIAVSASTIPEQIQSLSVHDSQGPPNANE  4148
 STE20/SPS1-related  DYR
  proline-alanine rich protein  APAPAAPAAPAPAPAPAPAAQAVGWPIC(1)RDAYE
 kinase  (STK39)   4802
   LQEVIGSGATAVVQAAL
71834853 prostate  speciﬁ  c antigen isoform  QCVDLHVISNDVC(1)AQVHPQK  2291
 3  preproprotein  (PSA) 
16445393  cadherin 12, type 2     -
 preproprotein  (CDH12)
7656967  cadherin EGF LAG seven-pass   PVVHIQAVDADSGENARL  1891
  G-type receptor 1 (CELSR1) SFAGPIGAVIIINTVTSVLSAKVSCQRK  2859 
   YVV(5)GWGIPAIVTGLAVGLDPQGYGNPDF  2897 
   ADIGGMLPGLTVRSVVVGGASEDKVSVRRGF  3129
   DLAATQDADFHEDVIHSGSALLAPATRAAW  3149
11056046 immunoglobulin  superfamily,  GTYLTHEAKGSDDAPDADTAIINAEGGQSGGDD  4056
  member 4B (IGSF4B) KKEYFI
1708887  LU_HUMAN Lutheran blood    -
  group glycoprotein precursor (LU)
9297107  NRP1_HUMAN Neuropilin-1    GGIAVDDISINNHISQEDC(1)AKPADLDK  2896
 precursor  (Vascular  endothelial  EGEIGKGNLGGIAVDDISINNHISQEDCAK  3096
  cell growth factor 165 receptor)  GM(4)ESGEIHSDQITASSQYSTNWSAERSRL  3243
 ( NRP1) 
62512184  SEL1L_HUMAN Sel-1   KPALTAIEGTAHGEPC(1)HFPF  2181
 homolog  (SEL1L)
4557575  fatty acid amide hydrolase (FAAH)   -
12751475  solute carrier family 39 (zinc   DSQQPAVLEEEEVMIAHAHPQEVYNEY  3155
  transporter), member   GQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR  4882
 6  (SLC39A6) YSREEL
    
10716563 calnexin  precursor  (CANX) GTAIVEBHDGHDDDVIDIEDDLDDVIEEVEDSKPD  4630
   TTAPPSSPK 
14916999  GRP78_HUMAN 78 kDa  DVSLLTIDNGVFEVVATNGDTHLGGEDF  2934
 glucose-regulated  protein
 precursor  (GRP78) NTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLT  4356
   KDNHL
117501 CRTC_HUMAN  Calreticulin  YTLIVRPDNTYEVKIDNSQVESGSL  2840
 precursor  (CRP55)  (Calregulin)
 (HACBP)  (ERp60)  (CRTC)